NY-ESTÉE-LAUDER
25.6.2020 14:02:08 CEST | Business Wire | Press release
This week, The Estée Lauder Companies (NYSE:EL) announced that Jane Hertzmark Hudis has been promoted to Executive Group President, effective July 1, 2020. She will continue to report directly to Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies (ELC), with brand portfolio oversight of Estée Lauder, La Mer, Bobbi Brown, AERIN, Origins, Aveda, Bumble and bumble, Dr. Jart+ and Do The Right Thing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005430/en/
As one of the most accomplished, visionary executives in the prestige beauty industry, Jane is highly regarded for her track record of building and leading global brands. In her elevated role, Jane’s portfolio reflects several of the highest growth areas of the Company, including skin care and driving success across China and APAC, as well as with Chinese consumers around the world.
“This well-deserved promotion recognizes Jane’s exceptional leadership across the Company,” said Mr. Freda. “Throughout her career, she has made a significant impact driving brand-building expertise, spearheading the elevation of marketing and talent, and leading her portfolio of brands to achieve outstanding broad-based growth across categories, regions and channels. I am grateful to Jane for all that she has done to drive the Company’s success and as an advisor to me, and I know that she will continue to lead and inspire us to even greater heights in the future.”
As an enterprise-wide leader, most recently as Group President, Jane has been the Company’s top skin care strategist, helping to drive expertise in this critical area. Today, Estée Lauder is the number one brand in skin care globally, and La Mer is the number one brand in luxury skin care globally. A champion of the Company’s hero franchise strategy, she has driven innovation and built iconic franchises including Estée Lauder’s Advanced Night Repair and La Mer’s Créme de La Mer. The outstanding results of her brands are a testament to her strategic vision, expertise in local relevance, exceptional talent for driving innovation in product and consumer marketing, and digital communication.
A passionate advocate of leadership development and inclusion and diversity throughout her career, Jane co-founded ELC’s Women’s Leadership Network in 2017 to inspire and engage women across the organization, helping them become exceptional leaders and mentors. In partnership with co-executive sponsors Tracey T. Travis, Executive Vice President and Chief Financial Officer and Sara E. Moss, Vice Chairman, Jane has expanded the Women’s Leadership Network to over 2,000 members globally, with local chapters in France and the United Kingdom.
Jane’s expertise has been widely recognized by many best-in-class organizations. She serves on the Board of Tiffany & Co. and as a Director of the Fashion Institute of Technology (FIT) Foundation, as well as on the Advisory Board of the Breast Cancer Research Foundation.
Prior to her promotion to Group President in 2016, Jane served for seven years as Global Brand President, Estée Lauder, where she led the brand’s modernization and digital evolution to attract a new generation of global consumers. She solidified Estée Lauder's position as a global leader in high-performance prestige skin care and makeup, growing net sales by more than 40 percent and establishing it as the number one brand in its prestige distribution in Asia. Preceding her leadership of Estée Lauder, Jane served in a number of key leadership roles at the Company, including President of Origins and BeautyBank, a brand innovation think tank she founded in 2003.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc.
is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced and Dr. Jart+.
ELC-C
ELC-B
ELC-L
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005430/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
